Comparison

PE-Labeled Human EGFRvIII Protein, His Tag (Site-specific conjugation) European Partner

Item no. EGI-HP2E3-200tests
Manufacturer ACROBiosystems
Amount 200 tests
Category
Type Proteins Recombinant
Format Powder
Specific against Human
Host HEK293
Conjugate/Tag HIS, PE
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias EGFRvIII
Available
Manufacturers Category
Protein / Fluorescent labeled protein
Description
PE-Labeled Human EGFRvIII, His Tag (EGI-HP2E3) is produced via site-specific conjugation of PE to Human EGFRvIII (25-378), His Tag under optimal conditions with a proprietary technology. Human EGFRvIII, His Tag (EGI-HP2E3) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Molecule
EGFRvIII
Exp Region
Leu 25 - Ser 378
Storage
-20℃, aviod light
Shipping
RT
Stability
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Molecular Weight
42.2 kDa
Characteristics
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 42.2 kDa.
Buffer
PBS, 0.5% BSA, pH7.4
Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 200 tests
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close